Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma

被引：0
|
作者：
S Diem
B Kasenda
L Spain
J Martin-Liberal
R Marconcini
M Gore
J Larkin
机构：
[1] Royal Marsden Hospital NHS Foundation Trust,Department of Medical Oncology
[2] Vall d’Hebron University Hospital,Department of Medical Oncology
[3] Vall d’Hebron Institute of Oncology (VHIO),Department of Medical Oncology
[4] Santa Chiara Hospital,undefined
来源：
British Journal of Cancer | 2016年 / 114卷
关键词：
melanoma; anti-PD-1; lactate dehydrogenase; marker; response; survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：256 / 261
页数：5
相关论文
共 50 条
  • [1] Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma
    Diem, S.
    Kasenda, B.
    Spain, L.
    Martin-Liberal, J.
    Marconcini, R.
    Gore, M.
    Larkin, J.
    [J]. BRITISH JOURNAL OF CANCER, 2016, 114 (03) : 256 - 261
  • [2] A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma
    Weber, Jeffrey S.
    Sznol, Mario
    Sullivan, Ryan J.
    Blackmon, Shauna
    Boland, Genevieve
    Kluger, Harriet M.
    Halaban, Ruth
    Bacchiocchi, Antonietta
    Ascierto, Paolo A.
    Capone, Mariaelena
    Oliveira, Carlos
    Meyer, Krista
    Grigorieva, Julia
    Asmellash, Senait G.
    Roder, Joanna
    Roder, Heinrich
    [J]. CANCER IMMUNOLOGY RESEARCH, 2018, 6 (01) : 79 - 86
  • [3] Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy
    Joseph, Richard W.
    Cappel, Mark
    Goedjen, Brent
    Gordon, Matthew
    Kirsch, Brandon
    Gilstrap, Cheryl
    Bagaria, Sanjay
    Jambusaria-Pahlajani, Anokhi
    [J]. CANCER IMMUNOLOGY RESEARCH, 2015, 3 (01) : 18 - 22
  • [4] Pretreatment Serum Lactate Dehydrogenase and Metastases Numbers as Potential Determinants of Anti-PD-1 Therapy Outcome in Nasopharyngeal Carcinoma
    Ali, Wael A. S.
    Huang, Xinxin
    Wu, Yuehan
    Ma, Yuxiang
    Pan, Hui
    Liao, Jun
    Yang, Zhang
    Hong, Shaodong
    Yang, Yunpeng
    Huang, Yan
    Zhao, Yuanyuan
    Fang, Wenfeng
    Zhao, Hongyun
    Zhang, Li
    [J]. CANCER CONTROL, 2023, 30
  • [5] Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma
    Kubo, Yosuke
    Fukushima, Satoshi
    Inamori, Yukiko
    Tsuruta, Mina
    Egashira, Sho
    Yamada-Kanazawa, Saori
    Nakahara, Satoshi
    Tokuzumi, Aki
    Miyashita, Azusa
    Aoi, Jun
    Kajihara, Ikko
    Tomita, Yusuke
    Wakamatsu, Kazumasa
    Jinnin, Masatoshi
    Ihn, Hironobu
    [J]. JOURNAL OF DERMATOLOGICAL SCIENCE, 2019, 93 (01) : 33 - 40
  • [6] Limited-duration anti-PD-1 therapy for patients with metastatic melanoma
    Makela, Siru
    Kohtamaki, Laura
    Laukka, Marjut
    Juteau, Susanna
    Hernberg, Micaela
    [J]. ACTA ONCOLOGICA, 2020, 59 (04) : 438 - 443
  • [7] Resistance patterns to anti-PD-1 therapy in metastatic melanoma
    Ozgun, Alpaslan
    Sondak, Vernon K.
    Markowitz, Joseph
    [J]. CHINESE CLINICAL ONCOLOGY, 2016, 5 (06)
  • [8] Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy A meta-analysis
    Xu, Jun
    Zhao, Jianguo
    Wang, Jianfang
    Sun, Caiping
    Zhu, Xiaoling
    [J]. MEDICINE, 2021, 100 (14) : E25318
  • [9] Impact of age on toxicity in patients treated with anti-PD-1 therapy for melanoma
    Shah, Kaustav P.
    Song, Haocan
    Ye, Fei
    Salem, Joe-Elie
    Balko, Justin
    Johnson, Douglas B.
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [10] FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma
    Tan, A. C.
    Emmett, L.
    Lo, S.
    Liu, V.
    Kapoor, R.
    Carlino, M. S.
    Guminski, A. D.
    Long, G. V.
    Menzies, A. M.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (10) : 2115 - 2120
12345